The Chemours Company

First Quarter 2016 Earnings Presentation

May 3, 2016

Safe Harbor Statement

This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements, as further described in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended December 31, 2015. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow, which should not be considered as replacements of GAAP. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the schedules to the press release or the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA and Free Cash Flow to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at investors.chemours.com.

Highlights

Executing on all aspects of our five-point transformation plan

Began implementing TiO_2 price increases

Announced decision to invest in world-class facility to support growing Opteon™ demand

Improved working capital performance, ended quarter with strong cash balance

Announced sale of Clean & Disinfect business

Chemours™

1Q16 Overview

($ in millions unless otherwise noted)

First Quarter Financial Summary

	1Q16	1Q15	Δ Yr/Yr	4Q15	Δ Seq.
Net Sales	$1,297	$1,363	($66)	$1,360	($63)
Adj. EBITDA	128	145	(17)	132	(4)
Adj. EBITDA Margin (%)	*9.9*	*10.6*	*(0.7)*	*9.7*	*0.2*
Net Income (loss)	51	43	8	(86)	137
Adj. Net Income	11	59	(48)	5	6
EPS[1]	$0.28	$0.24	$0.04	($0.48)	$0.76
Adj. EPS[1]	$0.06	$0.33	($0.27)	$0.03	$0.03
Free Cash Flow[2]	($219)	($375)	$156	$175	($394)

Year-over-year

- Financial results lower primarily due to lower TiO_2 pricing and currency headwinds partially offset by Transformation Plan cost reductions
- Meaningful improvement in Free Cash Flow performance

Sequentially

- Benefits from cost reductions and Opteon™ growth tempered by lower pricing and licensing income

Chemours™

See reconciliation of non-GAAP measures in the Appendix

[1] Periods prior to 3Q15 are represented by pro forma basic and diluted EPS

[2] Defined as Cash from Operations minus cash used for PP&E purchases excluding benefit from DuPont prepayment of ~$166M at 3/31/16

Adjusted EBITDA Bridge: 1Q16 versus 1Q15

($ in millions)



Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Adjusted EBITDA Bridge: 1Q16 versus 4Q15



Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Liquidity Position

($ in millions)



- Free Cash Flow of ($53M) or ($219M) excluding DuPont prepayment benefit versus ($375M) in Q1 2015
- Quarter-end cash balance of $435M reflecting improved working capital performance, DuPont pre-payment and proceeds from Beaumont aniline sale
- Net debt of $3.6B
- Total Liquidity of ~$1.1B, including full revolver availability of $750M[1]
- Cash restructuring payments of $32M in Q1, full year still expected to be approximately $100 – 120M

[1] Based on Credit Agreement defined LTM Adjusted EBITDA, as amended February 2016, including pro forma adjustments, Senior Secured Net Debt/EBITDA of 1.6x
[2] Includes impact from gain on sale of Beaumont aniline facility
[3] Includes proceeds from sale of Beaumont aniline facility

Chemours™

Titanium Technologies Business Summary

First Quarter Highlights

- Volume consistent with seasonal and historic trend
- Began implementing price increase announced in December 2015; ended the quarter at higher price point
- Reduced operating costs and inventory position through transformation efforts
- Announced additional $150 per metric ton price increase, effective as contracts allow or after May 1, 2016, whichever comes first

Outlook Commentary

- Encouraged by early start to North American coatings season
- Price increase implementation ongoing
- Altamira on track for commercial start-up in the second quarter

Financial Summary *($ millions)*

	1Q16	1Q15	4Q15
Sales	$521	$545	$589
Adjusted EBITDA	$54	$93	$62
Adjusted EBITDA Margin (%)	*10.4*	*17.1*	*10.5*

Sales Drivers

	Yr/Yr % Δ
Price	(16)
Currency	(1)
Volume	13

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Fluoroproducts Business Summary

First Quarter Highlights

- Strong market adoption of Opteon™
- Seasonally lower refrigerant volumes partially offset by additional participation in broader polymer segments
- Consistent operations and transformation initiatives delivered lowered costs
- Announced decision to invest in next tranche of Opteon™ capacity using world-class technology

Outlook Commentary

- Continued growth of Opteon™ product line expected to sequentially ramp up with strong second half anticipated
- Lower quotas for base refrigerants, partially offset by higher pricing
- Continued competitive polymer environment offset by broader market participation
- Cost reduction initiatives ongoing

Financial Summary *($ millions)*

	1Q16	1Q15	4Q15
Sales	$531	$552	$515
Adjusted EBITDA	$85	$75	$80
Adjusted EBITDA Margin (%)	*16.0*	*13.6*	*15.5*

Sales Drivers

	Yr/Yr % Δ
Price	4
Currency	(5)
Volume	(3)

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Chemical Solutions Business Summary

First Quarter Highlights

- Beaumont aniline sale completed
- Continued cost reductions
- Lower pricing driven by lower input costs
- Announced sale of Clean and Disinfect (C&D) business to LANXESS for $230M in gross proceeds

Outlook Commentary

- Sulfur remains under strategic evaluation
- Anticipate C&D transaction to close in second half of the year
- Growth in North American gold market expected over next 3 – 5 years supporting need for cyanide expansion

Financial Summary *($ millions)*

	1Q16	1Q15	4Q15
Sales	$245	$266	$256
Adjusted EBITDA	$10	$1	$16
Adjusted EBITDA Margin (%)	*4.1*	*0.4*	*6.3*

Sales Drivers

	Yr/Yr % Δ
Price	(8)
Currency	(1)
Volume	3
Portfolio	(2)

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Progress on Transformation Plan

($ in millions)

Cost Reduction Progress



Other Transformation Activity

- Portfolio Optimization
  - Closed sale of Aniline facility
  - Began Shutdown process for Niagara RMS site
  - Implementing improvement plan for Methylamines business
  - Announced sale of C&D business
  - Evaluating Sulfur
- Growing Market Positions
  - Opteon™ expected to ramp up in 2016
  - Altamira TiO_2 facility set to begin commercial startup in Q2
  - Cyanides expansion project ongoing
- Refocusing Investments
  - Investing in world-class capacity expansion to serve growing demand for Opteon™

Chemours™

2016 Outlook Reaffirmed

2016 Adjusted EBITDA Expected to be Greater than 2015, including $200M of Transformation Savings, Generating Modestly Positive Free Cash Flow

Key Factors Influencing 2016 Performance:

Market Factors

- TiO_2 price
- Currency
- End-market demand

Chemours Initiatives

- Cost reductions
- Working capital productivity
- Ramp up in Opteon™
- Altamira start-up

Appendix

GAAP Net Income (Loss) to Adjusted EBITDA and Adjusted Net Income Reconciliations

($ in millions unless otherwise noted)

	Three months ended					
	March 31,				December 31,	
	2016		2015		2015	
Net income (loss) attributable Chemours	$	51	$	43	$	(86)
Non-operating pension and other postretirement employee benefit costs		(7)		7		(8)
Exchange losses		6		16		28
Restructuring charges		17		-		85
Asset impairments		-		-		3
(Gain) loss on sale of assets or business		(89)		-		9
Transaction, legal and other charges		8		-		17
Provision for (benefit from) income taxes relating to reconciling items [1]		25		(7)		(43)
Adjusted Net Income	$	11	$	59	$	5
Net income attributable to noncontrolling interests		-		-		-
Interest expense		57		-		53
Depreciation and amortization		66		64		66
All remaining (benefit from) provision for income taxes [1]		(6)		22		8
Adjusted EBITDA	$	128	$	145	$	132
Adjusted earnings per share, basic	$	0.06	$	0.33	$	0.03
Adjusted earnings per share, diluted	$	0.06	$	0.33	$	0.03

[1] Total of provision for (benefit from) income taxes reconciles to the amount reported in the interim consolidated statement of operations for the three months ended March 31, 2016 and 2015.

[2] On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings per common share for the three-months March 31, 2015 were calculated using the number of shares distributed on July 1, 2015.

Chemours™

Segment Net Sales and Adjusted EBITDA (unaudited)

($ in millions unless otherwise noted)

	Three months ended		
	March 31,		December 31,
	2016	2015	2015
SEGMENT NET SALES			
Titanium Technologies	$ 521	$ 545	$ 589
Fluoroproducts	531	552	515
Chemical Solutions	245	266	256
Total Company	$ 1,297	$ 1,363	$ 1,360
SEGMENT ADJUSTED EBITDA			
Titanium Technologies	$ 54	$ 93	$ 62
Fluoroproducts	85	75	80
Chemical Solutions	10	1	16
Corporate & Other	(21)	(24)	(26)
Total Company	$ 128	$ 145	$ 132
SEGMENT ADJUSTED EBITDA MARGIN			
Titanium Technologies	10.4%	17.1%	10.5%
Fluoroproducts	16.0%	13.6%	15.5%
Chemical Solutions	4.1%	0.4%	6.3%
Corporate & Other	0.0%	0.0%	0.0%
Total Company	9.9%	10.6%	9.7%

Chemours™

Chemours™

©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company